Safety and Efficacy of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Lewy Body Dementia and Amyloid-Beta Pathology (U01 - Clinical Trial Required) | RFA NS 25 010

FAQs: RFA-NS-25-010 (NIH U01) Anti-amyloid Antibodies in Mixed-Etiology Dementia with Emphasis on Lewy Body Dementias

1) What is the goal of this funding opportunity?

The opportunity (RFA-NS-25-010) seeks applications for placebo-controlled clinical trials to test whether FDA-approved monoclonal antibody therapies that target amyloid-beta are safe and effective in people with mixed-etiology dementia, with particular emphasis on Lewy Body Dementias (LBD). The focus is on generating clear clinical evidence in patient groups that are common in real-world clinics but often underrepresented in traditional Alzheimer disease trials.

2) What mechanism is being used (grant type), and what does it imply?

This is a U01 cooperative agreement. A cooperative agreement typically means NIH program staff will have substantial involvement compared with a standard research project grant. Applicants should plan for an active partnership model that may include coordination on milestones, reporting expectations, and possible harmonization across funded projects if multiple awards are made.

3) Are applicants expected to develop new drugs or test existing therapies?

The intent is not to develop new drugs. The trials are meant to rigorously evaluate existing, FDA-approved anti-amyloid monoclonal antibodies in the target mixed-etiology dementia populations.

4) What kind of trial design is required?

The trials must be placebo-controlled and designed to determine both efficacy and safety of the anti-amyloid antibody therapy compared with placebo in the specified mixed dementia groups.

5) Which patient population is the main focus of the trials?

The population of interest includes people with mild cognitive impairment or dementia who show canonical biomarkers of Alzheimer-type pathology and also meet clinical criteria for Lewy body-related dementia. The emphasis is on overlapping pathologies rather than treating Alzheimer disease and LBD as completely separate conditions.

6) Which Lewy body dementia syndromes are specifically highlighted?

The NOFO specifically focuses on clinically diagnosed dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD).

7) What Alzheimer-type biomarkers are mentioned as examples of eligibility evidence?

Examples highlighted include amyloid deposition on PET imaging and/or cerebrospinal fluid profiles consistent with amyloid pathology, such as low Abeta42 in combination with elevated phosphorylated tau.

8) What outcomes must the trials evaluate?

The trials must be designed to evaluate both efficacy and safety of the anti-amyloid antibody therapy compared with placebo in the targeted mixed-etiology dementia groups.

9) Does the NOFO encourage any particular statistical methods or trial designs?

Yes. The NOFO explicitly encourages modern statistical and trial-design approaches, especially Bayesian methods and response-adaptive randomization. The stated intent is to learn efficiently and to examine whether particular subgroups respond differently while maintaining rigor and interpretability.

10) What does "response-adaptive randomization" mean in the context of this opportunity?

Based on the description in the opportunity, response-adaptive randomization refers to designs that can adapt based on accumulating data during the trial, while still preserving the rigor needed to produce decision-quality results.

11) Are subgroup analyses part of the funding opportunity's interests?

Yes. The NOFO signals interest in examining whether particular subgroups respond differently, alongside overall assessments of safety and efficacy.

12) What expectations are stated for sample size and statistical power?

A central requirement is that proposed studies be adequately powered. Applications should show that the study design and enrollment plans support interpretable conclusions about safety and efficacy in the target population.

13) What does NIH expect regarding demographic and geographic representation?

Applications are expected to include recruitment and retention plans that achieve meaningful representation by sex, race and ethnicity, and geography. The expectation is that the study sample should resemble the real distribution of these conditions in the United States, which typically requires deliberate planning and ongoing monitoring of enrollment metrics.

14) What kinds of strategies are suggested to improve representativeness?

The opportunity points to approaches such as deliberate site selection, community partnerships, culturally competent outreach, and careful monitoring of enrollment metrics throughout the trial.

15) Is patient and community engagement required, and how intensive should it be?

Yes. The NOFO emphasizes patient and community engagement and states that engagement elements must be built into all stages of program development and embedded at every level of the organizational structure. The intent is continuous, operational engagement rather than a one-time advisory activity.

16) What are examples of patient and community engagement activities described in the opportunity?

Examples include involving patients and care partners in protocol development; improving feasibility and acceptability of study procedures; informing outcome selection; shaping recruitment materials; advising on participant burden and accessibility; and supporting dissemination of results back to participating communities.

17) How might the cooperative agreement structure affect project management?

Because NIH program staff are expected to have substantial involvement, applicants should anticipate coordination with NIH around milestones, reporting, and potentially harmonization across funded projects if multiple awards are made.

18) Who is eligible to apply?

Eligibility is broad across U.S.-based organizations, including (among others) state, county, and local governments; public and private institutions of higher education; federally recognized tribal governments; tribal organizations; independent school districts; special district governments; public housing authorities; nonprofits (with or without 501(c)(3) status); for-profit organizations (other than small businesses) as well as small businesses; and other entities.

19) Are specific institution types called out as eligible?

Yes. The NOFO also calls out eligible applicant types such as Historically Black Colleges and Universities, Hispanic-serving institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, faith-based and community-based organizations, regional organizations, U.S. territories or possessions, and eligible federal agencies.

20) Are foreign (non-U.S.) organizations eligible to apply?

No. Foreign (non-U.S.) entities are not eligible to apply.

21) Are non-U.S. components of U.S. organizations allowed?

No. Non-U.S. components of U.S. organizations are not eligible.

22) Are any international activities allowed at all?

Yes. Foreign components, as defined by NIH policy, are allowed. This generally means discrete elements of the project may be performed abroad when well-justified and compliant with NIH rules.

23) What is the application due date listed in the opportunity?

The listing includes an original application due date of January 24, 2025.

24) What is the award ceiling?

The listing includes an award ceiling of $6,700,000.

25) What CFDA numbers are associated with this opportunity?

The listing classifies the opportunity under CFDA numbers 93.853 and 93.866.

26) What real-world clinical gap is this opportunity trying to address?

The opportunity targets a common real-world scenario: individuals who have biological evidence of Alzheimer-type pathology and a clinical diagnosis of Lewy body-related dementia. These mixed-etiology patients are often underrepresented in traditional Alzheimer disease trials, and the NOFO aims to produce evidence that is generalizable to the diverse U.S. populations affected.

27) What does "placebo-controlled" imply for these trials?

Based on the NOFO description, placebo-controlled means the anti-amyloid antibody therapy is compared against a placebo group to rigorously evaluate both efficacy and safety in the targeted mixed dementia populations.

28) What is the overall evidence the NIH wants from these studies?

The opportunity is aimed at generating clear clinical evidence about whether anti-amyloid antibody treatment helps, harms, or has a mixed profile in people who have both Alzheimer-type amyloid biology and clinically diagnosed Lewy body dementia syndromes, while ensuring results are generalizable across diverse U.S. populations.